Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022Jon Salmanton‐García, Summiya Nizamuddin, Martin Schönlein et al.|EClinicalMedicine|2024Cited by 34
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Pau Montesinos, Juan Manuel Alonso‐Domínguez et al.|Scientific Reports|2021Cited by 25
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Bruno Paiva et al.|Blood Advances|2021Cited by 25
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findingsGiuseppe Rossi, И. О. Стома, Jon Salmanton‐García et al.|International Journal of Infectious Diseases|2023Cited by 16
The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi TrialAdrián Mosquera Orgueira, Pau Montesinos, Manuel Pérez‐Encinas et al.|Blood|2023Cited by 15